Ikena Oncology, Inc. (IKNA)

Ikena Oncology Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	9.16	15.62	30.99	9.19
Revenue Growth (YoY)	-	-41.35%	-49.59%	237.01%	-33.15%
Cost of Revenue	30.88	59.65	64.32	47.11	44.85
Gross Profit	-30.88	-50.49	-48.7	-16.12	-35.65
Selling, General & Admin	23.68	24.93	22.2	18.02	8.87
Operating Expenses	23.68	24.93	22.2	18.02	8.87
Operating Income	-54.55	-75.42	-70.9	-34.14	-44.52
Interest & Investment Income	7.37	7.11	2.15	0.02	-
Other Non Operating Income (Expenses)	2.52	-0.02	-0.01	-	0.26
EBT Excluding Unusual Items	-44.66	-68.33	-68.77	-34.12	-44.26
Merger & Restructuring Charges	-4.42	-	-	-	-
Pretax Income	-49.08	-68.33	-68.77	-34.12	-44.26
Income Tax Expense	0.15	-0.16	-	-	-
Net Income	-49.23	-68.17	-68.77	-34.12	-44.26
Net Income to Common	-49.23	-68.17	-68.77	-34.12	-44.26
Shares Outstanding (Basic)	48	42	36	28	3
Shares Outstanding (Diluted)	48	42	36	28	3
Shares Change (YoY)	15.63%	15.33%	29.32%	911.88%	4.43%
EPS (Basic)	-1.02	-1.63	-1.90	-1.22	-16.00
EPS (Diluted)	-1.02	-1.63	-1.90	-1.22	-16.00
Free Cash Flow	-46	-80.16	-75.54	-62.01	-38.59
Free Cash Flow Per Share	-0.95	-1.92	-2.09	-2.22	-13.96
Gross Margin	-	-	-	-52.03%	-
Operating Margin	-	-823.33%	-453.99%	-110.18%	-484.22%
Profit Margin	-	-744.17%	-440.29%	-110.10%	-481.36%
Free Cash Flow Margin	-	-875.08%	-483.67%	-200.14%	-419.75%
EBITDA	-54.06	-74.4	-70.15	-33.59	-44.22
EBITDA Margin	-	-	-	-108.42%	-
D&A For EBITDA	0.49	1.02	0.75	0.54	0.3
EBIT	-54.55	-75.42	-70.9	-34.14	-44.52
EBIT Margin	-	-	-	-110.18%	-

Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q